Human CD19 (20-291), Fc Tag (CD9-H5259) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).
Predicted N-terminus: Pro 20
Request for sequence
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 56.3 kDa. The protein migrates as 56-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 0.1 EU per μg by the LAL method.
The sterility testing was performed by membrane filtration method described in USP <71> and Eur. Ph. 2.6.1.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 6 months under sterile conditions after reconstitution.
Human CD19 (20-291), Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized FMC63 at 1 μg/mL (100 μL/well) can bind Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5259) with a linear range of 0.039-0.625 μg/mL (QC tested).
Immobilized Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5259) at 5 μg/mL (100 μL/well) can bind FMC63 with a linear range of 0.6-20 ng/mL (QC tested).
Human CD19 (20-291), Fc Tag (Cat. No. CD9-H5259) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Monoclonal Anti-Human CD19 Antibody (Mouse IgG2a) with an affinity constant of 0.467 nM as determined in a SPR assay (Biacore 8K) (QC tested).
Deep-learning based three-dimensional label-free tracking and analysis of immunological synapses of chimeric antigen receptor T cells. BioRxiv preprint. doi: https://www.biorxiv.org/content/10.1101/539858v1
Authors: M Lee, et al
Journal: BioRxiv 2019
Application: Flow cytometry
Authors: Hsu H, et al.
Journal: J Immunol 2018
Application: Granule mobilization assay
Authors: De Oliveira SN, et al.
Journal: J Transl Med 2013
Application: Flow cytometry
B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.